Fatal outcome in experimental gene therapy trial prompts investigation into data transparency

A six-year-old patient died shortly after receiving an experimental gene therapy, with investigations revealing potential failures to report critical safety data. The incident highlights systemic concerns regarding clinical trial oversight and the transparency of adverse event reporting in gene therapy research.